Navigation Links
Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
Date:6/26/2012

BILLERICA, Mass., June 26, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

The XF Palmitate-BSA FAO Reagent is a pre-conjugated, quality controlled fatty acid substrate in an aqueous solution that is readily absorbed and utilized by cells. Traditionally, FAO assays have been dependent on the Palmitate solubilizing, which is difficult to achieve and produces variable data.  

"For researchers probing substrate utilization and fatty acid oxidation pathways, the process is no longer dependent on one's ability to prepare Palmitate. Each lot of the Seahorse XF Palmitate-BSA Reagent is functionally tested for activity in a fatty acid oxidation assay on the XF Analyzer, ensuring consistent performance; and the pre-conjugated, non-radioactive, ready-to-use solution eliminates any requirement of a lengthy conjugation protocol, so the assay is no longer intimidating to the researcher", stated Steve Chomicz, Seahorse Vice President of Sales, Marketing & Support.

For use with both the XF96 and XF24 Extracellular Flux Analyzers, the new XF Palmitate-BSA FAO Reagent introduces a standardized, ready-to-use, quality-controlled solution for measuring fatty acid oxidation providing true functional information, and consistent results in every assay, without radioactivity.

The XF Palmitate-BSA FAO Reagent will further advance the study of cellular bioenergetics, helping scientists to better understand the connection of physiological traits of cells with genomic and proteomic data. This knowledge will generate new insights into cellular bioenergetics and mitochondrial dysfunction, leading to a greater understanding, and new treatments of diseases as the human lifespan increases.

About Seahorse Bioscience

Seahorse Bioscience provides instrumentation and kits for cellular bioenergetic analysis for biological research and drug discovery applications. Over 1,500 scientists worldwide are advancing their research in understanding the role of metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Toxicology, Immunology, Obesity, Diabetes, Metabolic Disorders, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China.

CONTACT: Naomi Goumillout, +1-978-671-1619, ngoumillout@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemaClear Launches Activity in APAC
2. Elsevier Launches New Journal: Learning, Culture and Social Interaction
3. Bode Technology Launches Same-Day DNA Service For Faster Response to Law Enforcement and Justice System
4. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
5. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
6. Pittcon 2013 Launches New Website
7. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
8. Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager
9. AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
10. Neogen launches the fastest molecular pathogen test
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):